Zynerba Pharmaceuticals — Investor Presentation (December 2022)
36 slides from Zynerba Pharmaceuticals's investor presentation, Dec 21, 2022
Slide 1: Advancing Science. Improving Connections.
© 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. December 2022
Slide 2: Forward-Looking Statements
Forward - Looking Statements The statements in this presentation may include forward - looking statements within the meaning of the private securities litigati on reform act of 1995. These statements, among other things relate to the future operations, opportunities, or financial performance of Zy n
Slide 3: A different and exciting approach to Cannabidiol
A different and exciting approach to Cannabidiol
Slide 4: An Orphan-Focused Neuropsychiatric, Biopharmaceutical Company
An Orphan - Focused Neuropsychiatric, Biopharmaceutical Company Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 4 Permeation - enhanced Patent - protected through 2040 Pharmaceutically manufactured; THC free FIRST AND ONLY TRANSDERMAL CANNABIDIOL GEL One Phase 3 clinical program
Slide 5: Benefits of Our Approach to Cannabidiol
Benefits of Our Approach to Cannabidiol Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 5 FDA regulated Consistency of production Purity of ingredients No THC – not a scheduled drug by U.S. DEA Scalable production process PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL DISPENSARY Eas
Slide 6: Clinical Development Programs
Clinical Development Programs Fragile X Syndrome FXS 22q Deletion Syndrome 22q
Slide 7: Overlap of Symptoms Across Conditions
Overlap of Symptoms Across Conditions Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 7 Anxiety Seeks Isolation Social Avoidance Lack of Interaction Attention Deficits Irritability FXS 22q December 2022
Slide 8: Focused Clinical Pipeline
Fragile X Syndrome (FXS) Focused Clinical Pipeline Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 8 Preclinical Phase 1 Phase 2 Pivotal Market 22q Deletion Syndrome (22q) Regulatory Filing U.S. Orphan Drug and Fast Track designations; EU Orphan Drug designation U.S. Orphan Drug
Slide 9: Well-Tolerated Safety Profile
• Majority of treatment - emergent AEs (TEAEs) were mild or moderate • Most common Zygel - related • No clinically significant changes in vital signs or ECGs • No Zygel - related clinically significant changes in laboratory values, including liver function tests Zynerba Pharmaceuticals | Advancing S
Slide 10: Fragile X Syndrome
[ : Fragile X Syndrome eh Ce
Slide 11: What is Fragile X Syndrome (FXS)?
~78K U.S. PATIENTS What is Fragile X Syndrome (FXS)? Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 11 • Leading known cause of inherited intellectual disability and autism spectrum disorder • Mutation of the FMR1 gene causes endocannabinoid system (ECS) dysregulation • Easily i
Slide 12: Poised for Success in FXS
Poised for Success in FXS Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 12 Largest clinical trial ever conducted in children with FXS Extensive safety database Patients on drug for up to five years Statistically significant outcomes in children with complete methylation Lessons
Slide 13: Role of FMR1 Methylation in FXS
Role of FMR1 Methylation in FXS Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 13 • FMR1 gene codes for production of FMRP* which is vital to synapse development • Methylation of the FMR1 gene plays a role in determining gene function • When methylation of the FMR1 gene silences
Slide 14: CONNECT-FX Key Learning: Results with complete methylation
CONNECT - FX Trial Key Learning: Results with complete methylation of FMR1 gene Consistent Improvements Observed with Zygel vs. Placebo in Patients with Complete Methylation Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 14 PRIMARY ENDPOINT CAREGIVER REPORTED BEHAVIOR CHANGE CLI
Slide 15: Clinically Meaningful Improvement in Patients with Complete Methylation
Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 15 Clinically Meaningful Improvement a Achieved and Maintained in Patients with Complete Methylation b 0 10 20 30 40 50 60 70 80 90 100 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Cumulative Percentage of Patients Month Zygel (n=47) Pl
Slide 16: CONNECT-FX Data Published in the Journal of Neurodevelopmental Disorders
CONNECT - FX Data Published in the Journal of Neurodevelopmental Disorders Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 16 December 2022 • “…ZYN002 was well tolerated in patients with FXS and demonstrated evidence of efficacy with a favorable benefit risk relationship in patie
Slide 17: Design Optimized from CONNECT-FX Trial
Design Optimized from CONNECT - FX Trial Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 17 More patient and family friendly Extending trial to 18 - weeks Increased dosing option for individuals >50 kg Successful completion of Phase 3 pivotal trial expected to satisfy requirement
Slide 18: Confirmatory Pivotal Trial Design
Confirmatory Pivotal Trial Design Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 18 Double - Blind, Placebo - Controlled Study: Initiated 18 weeks Zygel (n~100; 80*) 250 mg daily (≤30kg) 500 mg daily (>30kg) 750 mg daily (>50kg) (weight - based dose) Placebo (n~100; 80*) Mirrors
Slide 19: Trial Objectives
Trial Objectives Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 19 Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale in patients who have complete (100%) methylation of their FMR1 gene • Change from baseline to end of treatment in: • ABC - C FXS I
Slide 20: Next Steps in FXS
Next Steps in FXS Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 20 Continued RECONNECT pivotal trial enrollment Topline results expected in 1H 2024 November 2022
Slide 21: 22q11.2 Deletion Syndrome (22q)
22q11.2 Deletion Syndrome (22q) Image courtesy Positive Exposure © 2016 Positive Exposure. All rights reserved. www.PositiveExposure.org . Eliza, living with 22q11.2 deletion syndrome
Slide 22: What is 22q11.2 Deletion Syndrome (22q)?
What is 22q11.2 Deletion Syndrome (22q)? Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 22 • Rare disorder and second most common genetic disorder, behind Down yndrome • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in
Slide 23: Rationale for Zygel in 22q
U.S. & EU ORPHAN DRUG DESIGNATION GRANTED FOR TREATMENT OF 22q Rationale for Zygel in 22q Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 23 • Overlapping symptoms with FXS and ASD • Associated with increased anxiety, irritability, social withdrawal and social interaction problem
Slide 24: INSPIRE Phase 2 Trial Design
INSPIRE Phase 2 Trial Design Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 24 Period 1: Completed 14 weeks Zygel (n = 20) 250 mg daily (≤35kg) 500 mg daily (>35kg) (weight - based dose) Period 2: Completed 24 weeks Efficacy assessments include: (week 14 vs baseline) • Anxiety,
Slide 25: INSPIRE Trial Results Summary
• Statistically significant improvements at 14 weeks and 38 weeks of treatment compared to baseline for multiple efficacy assessments: • The total score and all five subscales of the Anxiety, Depression and Mood Scale (ADAMS) • All five subscales of the Aberrant Behavior Checklist – Community (ABC -
Slide 26: Efficacy: Significant Improvement in Anxiety as Measured by the PARS-R
26 Efficacy: Significant Improvement in Anxiety as Measured by the PARS - R 14.7 8.5 0 2 4 6 8 10 12 14 16 PARS - R score 40.6% ( P =.0005) Baseline (n=15) Week 14 (n=15) 15.3 7.4 0 2 4 6 8 10 12 14 16 PARS - R score 49.4% ( P =.0001) Baseline (n=11) Week 38 (n=11) The efficacy analysis for Period 1
Slide 27: Efficacy: Significant Improvements in ADAMS Total and Subscale Scores
27 Efficacy: Significant Improvements in ADAMS Total and Subscale Scores Mean Scores and Percentage Improvement Period 1 14 weeks 36.1 10.4 7.6 8.7 3.0 7.6 17.7 5.1 3.4 4.3 1.1 4.4 0 5 10 15 20 25 30 35 40 Baseline (n=16) Week 14 (n=16) ADAMS total and subscale scores 45.3% ( P =.0005) 43.6% ( P= .0
Slide 28: Efficacy: Significant Improvements in All ABC-C Subscale Scores
28 Efficacy: Significant Improvements in All ABC - C Subscale Scores ABC - C subscale score 36.3% ( P =.0055) 18.3% ( P= .0166) 52.1% ( P= .0155) 16.5% ( P= .0091) 27.6% ( P= .011) 41.6% ( P =.0087) 63.3% ( P= .0028) 73.3% ( P= .0270) 48.1% ( P= .0232) 59.4% ( P= .0174) ABC - C subscale score Period
Slide 29: Next Steps in 22q
Next Steps in 22q Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 29 Ongoing discussions with FDA regarding regulatory pathway Initiate Phase 3 program after RECONNECT topline results December 2022
Slide 30: Positioned for Success
Positioned for Success
Slide 31: Leadership
Leadership Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 31 Armando Anido Chairman of the Board and CEO Terri B. Sebree President Jim Fickenscher CFO and VP, Corporate Development Paul Kirsch VP, Regulatory Affairs and Quality Assurance Joe Apostolico VP, Human Resources Terry
Slide 32: Financial Strength
Financial Strength Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 32 CASH AND CASH EQUIVALENTS $55.9M as of September 30, 2022; expected to be sufficient to fund operations and capital requirements to mid - year 2024 BALANCE SHEET CLEAN No debt, 47.1M shares outstanding (as of N
Slide 33: A Year of Clinical Progress Ahead
A Year of Clinical Progress Ahead Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 33 Pivotal trial results expected in 1H 2024 Finalize regulatory pathway with FDA in 2023; Initiate Phase 3 after RECONNECT topline results December 2022
Slide 34: Zynerba Vision for Future Growth
• Leader in transdermal cannabidiol delivery • Late - stage clinical company with two orphan CNS programs in areas of high unmet need • Launch Zygel in FXS via strategic partners in EU and other Territories • Launch Zygel into additional multi - billion $ market of 22q • Optimize Zygel growth with a
Slide 35: A different and exciting approach to Cannabidiol
A different and exciting approach to Cannabidiol
Slide 36: Thank you!
© 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Thank you!
Zynerba Pharmaceuticals — Investor Presentation (December 2022) on 6ix